Two Sigma Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $32.2M | Buy |
|
|||||
|
2025
Q2 | $37.9M | Buy |
|
|||||
|
2025
Q1 | $24.2M | Buy |
|
|||||
|
2024
Q4 | $18.8M | Buy |
|
|||||
|
2024
Q3 | $16.6M | Buy |
|
|||||
|
2024
Q2 | $11.9M | Sell |
|
|||||
|
2024
Q1 | $12.6M | Buy |
|
|||||
|
2023
Q4 | $13.6M | Sell |
|
|||||
|
2023
Q3 | $16.8M | Buy |
|
|||||
|
2023
Q2 | $15M | Sell |
|
|||||
|
2023
Q1 | $18.4M | Buy |
|
|||||
|
2022
Q4 | $22.6M | Sell |
|
|||||
|
2022
Q3 | $25.4M | Sell |
|
|||||
|
2022
Q2 | $22M | Buy |
|
|||||
|
2022
Q1 | $28.8M | Sell |
|
|||||
|
2021
Q4 | $29.8M | Buy |
|
|||||
|
2021
Q3 | $27.6M | Buy |
|
|||||
|
2021
Q2 | $11.2M | Buy |
|
|||||
|
2021
Q1 | $2.28M | Sell |
|
|||||
|
2020
Q4 | $9.76M | Sell |
|
|||||
|
2020
Q3 | $6.49M | Sell |
|
|||||
|
2020
Q2 | $10.1M | Buy |
|
|||||
|
2020
Q1 | $3.2M | Buy |
|
|||||
|
2019
Q4 | $5.18M | Buy |
|
|||||
|
2019
Q3 | $2.51M | Buy |
|
|||||
|
2019
Q2 | $1.67M | Buy |
|
|||||
|
2019
Q1 | $1.58M | Buy |
|
|||||
|
2018
Q4 | $1.33M | Sell |
|
|||||
|
2018
Q3 | $1.51M | Buy |
|
|||||
|
2018
Q2 | $970K | Buy |
|
|||||
|
2018
Q1 | $447K | Sell |
|
|||||
|
2017
Q4 | $464K | Buy |
|
|||||
|
2017
Q3 | $448K | Buy |
|
|||||
|
2017
Q2 | $353K | Buy |
|
|||||
|
2017
Q1 | $255K | Buy |
|
|||||
|
2015
Q1 | – | Sell |
|
|||||
|
2014
Q4 | $178K | Sell |
|
|||||
|
2014
Q3 | $224K | Sell |
|
|||||
|
2014
Q2 | $760K | Buy |
|